APR-246 in Combination With Venetoclax and Azacitidine in TP53-Mutant Myeloid Malignancies

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-12-13

Study Completion Date

2022-01-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This clinical trial is a Phase I, open-label, dose-finding and cohort expansion study to determine the safety and preliminary efficacy of APR-246 in combination with venetoclax and azacitidine in patients with myeloid malignancies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms

NCT03072043

Myelodysplastic Syndrome Acute Myeloid Leukemia Myeloproliferative Neoplasm +1 more

COMPLETED PHASE1/PHASE2

APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant

NCT03931291

Acute Myeloid Leukemia or Myelodysplastic Syndromes

COMPLETED PHASE2

Study of the Safety and Efficacy of APR-246 in Combination With Azacitidine

NCT03588078

Myelodysplastic Syndrome With Gene Mutation Acute Myeloid Leukemia With Gene Mutations Myeloproliferative Neoplasm +1 more

UNKNOWN PHASE1/PHASE2

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

NCT03745716

MDS

COMPLETED PHASE3

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

NCT06634394

Acute Myeloid Leukemia (AML)

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will enroll adult male and female patients of age ≥ 18 years with documented diagnosis of AML, according to WHO classification, and documented TP53 mutation which is not benign or likely benign, who also meet the eligibility requirements of this protocol.

The study will include a safety lead-in dose-finding portion followed by expansion portion. During the safety lead-in portion of the study, two cohorts will independently enroll patients following a 3 + 3 design. Each cohort will enroll up to 6 patients.

The expansion portion will begin once the recommended phase II dose (RP2D) of APR-246 in combination with venetoclax and in combination with venetoclax and azacitidine have been determined in order to assess the antitumor activity of these combinations.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myeloid Malignancy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

The study will include a safety lead-in dose-finding portion followed by the expansion portion. During the safety lead-in portion of the study, two cohorts will independently enroll patients following a 3 + 3 design.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

APR-246

APR-246 4.5 g/day

Group Type EXPERIMENTAL

APR-246

Intervention Type DRUG

APR-246 4.5 g/day

Venetoclax

Intervention Type DRUG

Venetoclax 400 mg once daily

Azacitidine

Intervention Type DRUG

Subcutaneous injection, or intravenous infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

APR-246

APR-246 4.5 g/day

Intervention Type DRUG

Venetoclax

Venetoclax 400 mg once daily

Intervention Type DRUG

Azacitidine

Subcutaneous injection, or intravenous infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed informed consent and ability to comply with protocol requirements.
2. Documented diagnosis of AML according to World Health Organization WHO) classification
3. Adequate organ function as defined by the following laboratory values:

1. Creatinine clearance \> 30 mL/min
2. Total serum bilirubin \< 1.5 × ULN
3. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< 3 × ULN
4. Age ≥18 years
5. At least one TP53 mutation
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2
7. Projected life expectancy of ≥ 12 weeks.
8. Negative serum or urine pregnancy test
9. Females of childbearing potential and males with female partners of childbearing potential must be willing to use an effective form of contraception

Exclusion Criteria

1. Prior treatment for TP53-mutant AML (\*dependent upon treatment arm assigned).
2. Known history of HIV or active hepatitis B or active hepatitis C infection.
3. Any of the following cardiac abnormalities:

1. Myocardial infarction within six months prior to registration;
2. New York Heart Association Class III or IV heart failure or known left ventricular ejection fraction (LVEF) \< 40%;
3. A history of familial long QT syndrome;
4. Symptomatic atrial or ventricular arrhythmias
5. QTcF ≥ 470 msec, unless due to underlying bundle branch block and/or pacemaker and with approval of the medical monitor.
4. Concomitant malignancies for which patients are receiving active therapy
5. Known active CNS involvement from AML.
6. Malabsorption syndrome
7. Pregnancy or lactation.
8. Active uncontrolled systemic infection (viral, bacterial or fungal).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No